Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective observational study of Japanese melanoma patients treated with combination therapy using nivolumab and ipilimiumab

Next Previous
Trial Profile

Prospective observational study of Japanese melanoma patients treated with combination therapy using nivolumab and ipilimiumab

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2018

At a glance

  • Drugs Ipilimumab/nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Nivo/Ipi Combi-POS

    • Most Recent Events

    • 13 Sep 2018 Status changed from not yet recruiting to discontinued.
    • 04 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top